Make an enquiry
Refer a patient
Patient Portal
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
2024-02-13T00:00:00.000+11:00
Ongoing

Ascent 07

Ascent 07
Breast cancer

A study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients with Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy. (Other title on ANZCTR)

A study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients with Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy. (Other title on ANZCTR)

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Breast cancer

Phase

III

Trial registration

Number: NCT05840211

Further information

Please click here for more information

GenesisCare Location(s)

GenesisCare North Shore 

GenesisCare North Shore  :::
Principal Investigator(s)

Dr Sally Baron-Hay

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.